Use of guidelines improves the neurological outcome in glutaric aciduria type IJana Herınger, Stefan Kölker, Georg F. Hoffmann et al.|Annals of Neurology|2010Cited by 169
Genotypic diversity and phenotypic spectrum of infantile liver failure syndrome type 1 due to variants in LARS1Dominic Lenz, Christian Staufner, Desirée E.C. Smith et al.|Genetics in Medicine|2020Cited by 49
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMASMichael Platten, Wolfgang Wick, Daniela Schilling et al.|Neuro-Oncology|2018Cited by 26
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Michael Platten, Wolfgang Wick, Daniela Schilling et al.|Journal of Clinical Oncology|2018Cited by 25
OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomasMichael Platten, Wolfgang Wick, Daniela Schilling et al.|Neuro-Oncology|2018Cited by 3